{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:12:15Z","timestamp":1778933535281,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1136\/ijgc-2021-002395","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T11:46:07Z","timestamp":1621338367000},"page":"1045-1051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treosulfan in platinum-resistant ovarian cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"Katrine Dam","family":"Olesen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja Tolstrup R\u00e6dkj\u00e6r","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Henrik","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina Dahl","family":"Steffensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stine Rauff","family":"S\u00f8ndergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2021-002395_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2021-002395_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/497429","article-title":"Treatment for recurrent ovarian cancer-at first relapse","volume":"2010","author":"Ushijima","year":"2010","journal-title":"J Oncol"},{"key":"10.1136\/ijgc-2021-002395_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/s40064-016-2660-0","article-title":"Management of relapsed ovarian cancer: a review","volume":"5","author":"Giornelli","year":"2016","journal-title":"Springerplus"},{"key":"10.1136\/ijgc-2021-002395_bb0025","unstructured":"Treatment of ovarian cancer. treatment guidelines . Available: http:\/\/www.skaccd.org\/index.php?option=com_docman&task=doc_view&gid=254&Itemid=101 [Accessed 9 Nov 2020]."},{"key":"10.1136\/ijgc-2021-002395_bb0030","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1517\/13543784.2010.515585","article-title":"Overcoming platinum resistance in ovarian carcinoma","volume":"19","author":"Matsuo","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1136\/ijgc-2021-002395_bb0035","unstructured":"Guidelines for visitation, diagnosis, treatment and follow-up of epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer and borderline tumoures 6. edition 2019 Chapter 5 - Version 20 03 2019 . Available: http:\/\/www.dgcg.dk\/images\/Grupper\/Ovariecancergruppen\/Retningslinier_2019\/Kapitel_5_OPDATERET_version_24_04_19_nye_koder.pdf [Accessed 9 Nov 2020]."},{"key":"10.1136\/ijgc-2021-002395_bb0040","author":"National Comprehensive Cancer Network","year":"2017","journal-title":"NCCN Guidelines Version 4.2007.pdf [Internet]"},{"key":"10.1136\/ijgc-2021-002395_bb0045","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00432-012-1221-3","article-title":"A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis","volume":"138","author":"Mahner","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1136\/ijgc-2021-002395_bb0050","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1517\/17425255.2013.737319","article-title":"Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan","volume":"9","author":"Galaup","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1136\/ijgc-2021-002395_bb0055","unstructured":"EMC . Treosulfan Capsules 250 mg - Summary of Product Characteristics (SmPC) - (emc) [Internet]. Available: https:\/\/www.medicines.org.uk\/emc\/medicine\/6426#gref [Accessed 2 Dec 2020]."},{"key":"10.1136\/ijgc-2021-002395_bb0060","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1006\/gyno.1998.4984","article-title":"Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study. The Danish Ovarian Cancer Study Group","volume":"69","author":"Keldsen","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002395_bb0065","first-page":"6869","article-title":"Treosulfan in the treatment of advanced ovarian cancer - results of a German multicenter non-interventional study","volume":"35","author":"Chekerov","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1136\/ijgc-2021-002395_bb0070","unstructured":"Gynecological Cancer Intergroup (GCIG) . CA 125 definitions agreed to by GCIG - November 2005.pdf [Internet]. Available: https:\/\/gcigtrials.org\/system\/files\/CA%20125%20Definitions%20Agreed%20to%20by%20GCIG%20-%20November%202005.pdf [Accessed 2 Nov 2020]."},{"key":"10.1136\/ijgc-2021-002395_bb0075","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2021-002395_bb0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2021-002395_bb0085","author":"US Department of Health and Human Services","year":"2017","journal-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [Internet]"},{"key":"10.1136\/ijgc-2021-002395_bb0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2009.04.026","volume":"114","author":"Meier","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002395_bb0095","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1006\/gyno.1998.5103","article-title":"Treosulfan as an effective second-line therapy in ovarian cancer","volume":"71","author":"Gropp","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002395_bb0100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/OTT.S30238","article-title":"Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options","volume":"6","author":"Elit","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.1136\/ijgc-2021-002395_bb0105","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1016\/j.ejca.2014.06.022","article-title":"Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab","volume":"50","author":"Steffensen","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2021-002395_bb0110","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/IGC.0000000000000334","article-title":"Clinical response to antiestrogen therapy in platinum-resistant ovarian cancer patients and the role of tumor estrogen receptor expression status","volume":"25","author":"Stasenko","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2021-002395_bb0115","doi-asserted-by":"crossref","DOI":"10.1186\/s40661-017-0040-2","article-title":"Preference of elderly patients to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial","volume":"4","author":"Chekerov","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"key":"10.1136\/ijgc-2021-002395_bb0120","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patient preferences for oral versus intravenous palliative chemotherapy","volume":"15","author":"Liu","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002395_bb0125","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00432-016-2307-0","article-title":"A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO)","volume":"143","author":"Sehouli","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1136\/ijgc-2021-002395_bb0130","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s002800051023","article-title":"Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer","volume":"45","author":"Hilger","year":"2000","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24005267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24005267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2021-002395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:38:44Z","timestamp":1753223924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24005267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1048891X24005267"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2021-002395","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treosulfan in platinum-resistant ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2021-002395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}